XOMA’s Acquisition of Royalty and Milestone Interest in Checkmate’s Vidutolimod from Kuros Biosciences

XOMA's Acquisition of Royalty and Milestone Interest in Checkmate’s Vidutolimod from Kuros Biosciences
Federica Tiefenthaler
Tagged:

Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest…

This content is for Standard 1 Year members only.
Login Join Now
Federica Tiefenthaler

Author: Federica Tiefenthaler

…

This content is for Standard 1 Year members only.
Login Join Now